While AstraZeneca's plan to spin off its China business could have some impact on the Chinese market, the iShares China Large-Cap ETF (FXI) is a diversified ETF with exposure to various sectors. As a result, the impact on FXI is likely to be limited in the short term.

Spinning off the China business could potentially unlock value for AstraZeneca and its shareholders by allowing the company to focus on its core operations and enabling the China business to grow independently. This could lead to a positive short-term impact on the stock price.